News

Madison Square Garden Held Talks About Moving to Hudson Yards

-Crain's New York Buisness https://www.crainsnewyork.com/transportation/madison-square-garden-held-talks-about-moving-hudson-yards

byCharles Gross

July 25, 2022

1 minute read

-Crain’s New York Buisness

https://www.crainsnewyork.com/transportation/madison-square-garden-held-talks-about-moving-hudson-yards

News

Adicet To Present Preclinical Data From Allogeneic Gamma Delta T Cell Platform At SITC 36th Annual Meeting

By Benzinga Newsdesk

Today, 7:43 PM

Adicet Bio, Inc. (NASDAQ:ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the Company will present data in

ACET

Wells Fargo Initiates Coverage On Taysha Gene Therapies with Overweight Rating, Announces Price Target of $25

By Benzinga Newsdesk

Today, 7:43 PM

Wells Fargo analyst Yanan Zhu initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight rating and announces Price Target of $25.

TSHA

Morgan Stanley Maintains Equal-Weight on American Equity Inv, Raises Price Target to $41

By Benzinga Newsdesk

Today, 7:43 PM

Morgan Stanley analyst Bob Huang maintains American Equity Inv (NYSE:AEL) with a Equal-Weight and raises the price target from $40 to $41.

AEL

FDA
News

Surface Oncology Presents Clinical Data On SRF617 At European Society For Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

By Benzinga Newsdesk

Today, 7:43 PM

Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that new data from the ongoing Phase

SURF

Madison Square Garden Held Talks About Moving to Hudson Yards

Related Posts

Adicet To Present Preclinical Data From Allogeneic Gamma Delta T Cell Platform At SITC 36th Annual Meeting

Wells Fargo Initiates Coverage On Taysha Gene Therapies with Overweight Rating, Announces Price Target of $25

Morgan Stanley Maintains Equal-Weight on American Equity Inv, Raises Price Target to $41

Surface Oncology Presents Clinical Data On SRF617 At European Society For Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021